SequelSEC

FibroBiologics, Inc. FBLG

Pharmaceutical Preparations · CIK 0001958777 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$4.03M
Fiscal year ended 2026-06-30
Free cash flow
-$3.29M
Fiscal year ended 2026-06-30

FibroBiologics, Inc. (FBLG) reported net income of -$4.12M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from FibroBiologics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

FibroBiologics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$4.03MUnavailable-$2.59M-$5.04MUnavailableUnavailable-$3.71M-$3.35MUnavailableUnavailable
Net income-$4.12MUnavailable-$3.24M-$5.78MUnavailableUnavailable-$3.10M-$500.00KUnavailableUnavailable
Research & development$1.66MUnavailable$797.00K$2.79MUnavailableUnavailable$1.36M$1.21MUnavailableUnavailable
Weighted-average diluted sharesshares 6.27MUnavailableUnavailableshares 43.07MUnavailableUnavailableUnavailableshares 33.52MUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0Unavailable$0$0UnavailableUnavailable$0$0UnavailableUnavailable
Diluted EPS$-0.66UnavailableUnavailable$-0.13UnavailableUnavailableUnavailable$-0.01UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.38MUnavailable$1.79M$2.25MUnavailableUnavailable$2.36M$2.14MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

FibroBiologics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$3.52MUnavailable$4.89M$4.87MUnavailableUnavailable$13.98M$7.83MUnavailableUnavailable
Total assets$7.93MUnavailable$9.62M$8.74MUnavailableUnavailable$16.44M$10.47MUnavailableUnavailable
Current assets$5.85MUnavailable$6.35M$5.24MUnavailableUnavailable$14.23M$8.20MUnavailableUnavailable
Total liabilities$3.29MUnavailable$3.46M$8.62MUnavailableUnavailable$13.71M$7.73MUnavailableUnavailable
Current liabilities$2.21MUnavailable$1.76M$6.72MUnavailableUnavailable$12.73M$6.68MUnavailableUnavailable
Total equity incl. NCI$4.64MUnavailable$6.16M$125.00KUnavailableUnavailable$2.74M$2.74MUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

FibroBiologics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$3.29MUnavailable-$3.16M-$3.97MUnavailableUnavailable-$3.07M-$2.61MUnavailableUnavailable
Capital expenditures$0Unavailable$0$6.00KUnavailableUnavailable$99.00K$11.00KUnavailableUnavailable
Investing cash flow$0Unavailable$0-$6.00KUnavailableUnavailable-$99.00K-$11.00KUnavailableUnavailable
Financing cash flow$5.32MUnavailable$3.19M$0UnavailableUnavailable$9.33M$4.47MUnavailableUnavailable
Net change in cash$2.03MUnavailable$27.00K-$3.98MUnavailableUnavailable$6.16M$1.85MUnavailableUnavailable
Stock-based compensation$707.00KUnavailable$702.00K$704.00KUnavailableUnavailable$544.00K$572.00KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

FibroBiologics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$3.29MUnavailable-$3.16M-$3.98MUnavailableUnavailable-$3.17M-$2.62MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.64xUnavailable3.61x0.78xUnavailableUnavailable1.12x1.23xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open FBLG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-31View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-31View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.